Investigational Drug Information for Ciraparantag
What is the development status for investigational drug Ciraparantag?
Ciraparantag is an investigational drug.
There have been 4 clinical trials for Ciraparantag.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 8th 2017.
The most common disease condition in clinical trials is [disabled in preview]. The leading clinical trial sponsors are Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc., Perosphere, Inc., and [disabled in preview].
There are eighteen US patents protecting this investigational drug and fifty-three international patents.
Summary for Ciraparantag
| US Patents | 18 |
| International Patents | 53 |
| US Patent Applications | 37 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2017-05-08) |
| Vendors | 26 |
Recent Clinical Trials for Ciraparantag
| Title | Sponsor | Phase |
|---|---|---|
| Study of Ciraparantag for Reversal of Anticoagulation Induced by Apixaban or Rivaroxaban in Healthy Adults | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Phase 2 |
| Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT | Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc. | Phase 2 |
| Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT | Perosphere, Inc. | Phase 2 |
Clinical Trial Summary for Ciraparantag
Top disease conditions for Ciraparantag
Top clinical trial sponsors for Ciraparantag
US Patents for Ciraparantag
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ciraparantag | ⤷ Start Trial | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Start Trial |
| Ciraparantag | ⤷ Start Trial | Ruthenium-sphingomyelin complexes and methods for their use in the treatment of tumors | ⤷ Start Trial | |
| Ciraparantag | ⤷ Start Trial | Oral drug dosage form comprising various release profiles | Triastek Inc | ⤷ Start Trial |
| Ciraparantag | ⤷ Start Trial | Thermally responsive anti-sag agents | Halliburton Energy Services Inc | ⤷ Start Trial |
| Ciraparantag | ⤷ Start Trial | Rapidly-orodispersible tablets having an in interior cavity | Aprecia Pharmaceuticals LLC | ⤷ Start Trial |
| Ciraparantag | ⤷ Start Trial | Thermally responsive lost circulation materials | Halliburton Energy Services Inc | ⤷ Start Trial |
| Ciraparantag | ⤷ Start Trial | Engineered platelets for targeted delivery of a therapeutic agent | Jpv01 Ltd | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ciraparantag
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ciraparantag | Australia | AU2017261372 | 2036-05-05 | ⤷ Start Trial |
| Ciraparantag | Canada | CA3023278 | 2036-05-05 | ⤷ Start Trial |
| Ciraparantag | China | CN107847398 | 2036-05-05 | ⤷ Start Trial |
| Ciraparantag | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Start Trial |
| Ciraparantag | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Start Trial |
| Ciraparantag | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Start Trial |
| Ciraparantag | Japan | JP2019520866 | 2036-05-05 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
